A Research Study to Evaluate the Efficacy and Safety of SGC001 in Patients With Anterior Wall ST-Segment Elevation Myocardial Infarction

Prior treatment

• Patients who have received thrombolysis;
• Febrile infection requiring systemic treatment within 2 weeks prior to screening;
• Concomitant left bundle branch block;
• Concomitant severe arrhythmia (including high-degree atrioventricular block, sick sinus syndrome, sustained ventricular tachycardia, etc.) or implanted cardiac pacemaker;

Other illness

• History of the following cardiac conditions:
  • History of myocardial infarction, coronary revascularization (including percutaneous coronary intervention \[PCI\] and coronary artery bypass grafting \[CABG\], etc.);
  • History of cardiopulmonary resuscitation;
  • History of stroke within 6 months;
  • Presence of severe cardiac structural abnormalities such as aortic dissection, and ventricular aneurysm;
• Definitive diagnosis of acute heart failure (Killip classification ≥ III; for details on Killip classification, see Appendix);
• Unable to undergo cardiac magnetic resonance (CMR) imaging according to the study protocol, or known allergy to any radiocontrast agent;

Other

• Patients with a life expectancy of less than 1 year;
• Cardiogenic shock or hemodynamic instability;

• 1.18-79 years of age (including boundary values), male or female;
• 2.Anterior wall STEMI: (a) history of persistent chest pain/precordial discomfort (\>30 minutes); (b) upon admission, the ECG must meet the following requirements: i.For male participants \>40 years old, ST-segment elevation ≥2 mm in leads V2 and V3; ii.For male participants ≤40 years old, ST-segment elevation ≥2.5 mm in leads V2 and V3; iii.For female participants, ST-segment elevation ≥1.5 mm in leads V2 and V3; If clinical symptoms of (a) are atypical, then (c) a positive point-of-care troponin test is required.
• 3.Planned for pPCI treatment;
• 4.Assessed as being able to complete dosing within 6 hours of the onset of persistent chest pain/precordial discomfort symptoms;
• 5.The participant or their legal guardian fully understands the objectives, nature, methods, and potential adverse reactions of the study, voluntarily agrees to participate, and has signed the informed consent form (ICF).